SHERIDAN, WYOMING - July 21, 2025 - Carestream Dental has reaffirmed its strategic commitment to innovation and customer partnership as dental professionals navigate a turbulent global market. In a direct message to the industry, CEO Lisa Ashby underscored the company's dedication to supporting practices facing inflation, market volatility, and shifting regulatory landscapes.

Ashby's statement highlights Carestream Dental's ongoing efforts to balance technological advancement with financial accessibility - a focus that positions the company as a resilient partner in times of economic uncertainty.

A Steadfast Commitment to Innovation

SHERIDAN, WYOMING - July 21, 2025 - Carestream Dental showcased its latest innovations in clinical productivity and patient care at IDS 2025 in Cologne, Germany, under the theme "Delivering What's Next." The company's presentation at Hall 11.1, C010, reflected its longstanding commitment to advancing dental technology and empowering practitioners worldwide.

Innovation That Builds on a Century of Leadership

"Asking the right questions and delivering the best solutions has made Carestream Dental a market leader for more than a century and has helped our customers deliver the best in oral healthcare," stated Lisa Ashby, CEO of Carestream Dental.

SHERIDAN, WYOMING – July 21, 2025 – Illinois' life sciences industry continues to demonstrate resilience and growth, underlining the state's standing as a regional powerhouse in biopharma employment. According to 2024 data from BIO and TEConomy Partners, Illinois employed 93,402 bioscience professionals across 4,926 businesses, marking a 7.5% increase in employment since 2019 — a growth trajectory that positions the state as a key hub within the BioMidwest Hotbed.

Steady Hiring Momentum in 2025

SHERIDAN, WYOMING – July 21, 2025 – Facing industry-wide uncertainty and hiring slowdowns, biopharma companies are increasingly turning to fractional roles to fill critical talent gaps—an emerging trend reshaping workforce strategies across the sector. Recent insights from recruiters and professionals reveal a growing openness to flexible, project-based roles that offer companies agility while providing experienced professionals with continued engagement in the field.

Fractional Work Gains Traction Amid Market Challenges

A July LinkedIn poll conducted by BioSpace indicated that 22% of respondents have experience with fractional roles, while an additional 54% are considering them. This shift is driven largely by a tightening job market and prolonged hiring timelines.

SHERIDAN, WYOMING – July 21, 2025 – The latest generation of biotech unicorns is navigating a challenging financial landscape, as AI-powered drug discovery ventures encounter tight investment conditions and a shrinking pool of exit opportunities. While their billion-dollar valuations once promised swift IPOs, today's market demands more strategic flexibility, operational discipline, and differentiated technologies.

Valuations Under Pressure in a Binary Outcome Industry

Valuations in biotech remain inherently speculative, often hinging on clinical outcomes that may take over a decade to materialize. “Biotech valuations remain speculative bets on binary clinical outcomes that typically take 10 to 15 years to materialize,” said Kaz Helal, senior biotech analyst at PitchBook. “Most biotechs only prove their true worth when Big Pharma writes the check at exit.”

SHERIDAN, WYOMING – July 21, 2025 – In a market often defined by bold strategies and high-stakes negotiations, five biotech CEOs have recently steered their companies into billion-dollar acquisitions — and each of them is a woman. These industry leaders not only shaped breakthrough therapies but also orchestrated some of the most high-profile M&A deals of recent years, underscoring the growing influence of women in biotech leadership.

Intra-Cellular Therapies: Sharon Mates’ Strategic Vision Realized in $14.6 Billion J&J Acquisition

Sharon Mates, founder, chairman, and CEO of Intra-Cellular Therapies, led the company from its 2002 inception to this year’s landmark $14.6 billion acquisition by Johnson & Johnson. Mates guided Intra-Cellular through key milestones, including FDA approvals for its atypical antipsychotic Caplyta in 2019 and 2021.

SHERIDAN, WYOMING – July 21, 2025 – Acadia Pharmaceuticals has presented an ambitious vision to transform itself from a small biotech player into a recognized powerhouse, leveraging a sharpened leadership focus and a pipeline with multi-billion-dollar potential. Marking a milestone in its 32-year history, the company recently hosted its inaugural R&D Day, unveiling strategic plans aimed at driving up to $12 billion in annual pipeline-driven revenue.

Leadership Duo Drives Strategic Realignment

SHERIDAN, WYOMING – July 21, 2025 – The American Diabetes Association’s 2025 Scientific Sessions spotlighted the evolving priorities of obesity drug development, emphasizing muscle preservation, improved tolerability, and novel molecular targets. With global analysts projecting the anti-obesity market to exceed $150 billion annually by the early 2030s, biopharmaceutical companies are racing to innovate beyond first-generation GLP-1 therapies.

Obesity Treatment Leaders Refocus on Patient Experience

SHERIDAN, WYOMING – July 21, 2025 – Audrey Greenberg, known for transforming the cell and gene therapy manufacturing landscape, has embarked on a new chapter as partner at Mayo Clinic’s newly established venture arm. Her move follows a career of strategic pivots across finance, real estate, and biomanufacturing — each driven by an unwavering focus on creating meaningful impact.

From Wall Street to Purpose-Driven Ventures

Greenberg’s professional journey began on Wall Street, a path she reconsidered after witnessing the 9/11 attacks firsthand. "I watched the towers fall, and I thought, what do I want to do that actually makes an impact on society, instead of just moving other people’s money around?" she reflected. This question led her to launch a real estate venture focused on tax credit housing, developing shelters for battered women and affordable housing for seniors in underserved communities.

SHERIDAN, WYOMING – July 21, 2025 – Sarepta Therapeutics has entered a critical phase of uncertainty after reports surfaced that the U.S. Food and Drug Administration (FDA) is considering requesting a halt to all shipments of its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. The potential move follows the disclosure of a third patient death associated with the company's underlying gene therapy platform.

FDA Scrutiny Intensifies After Third Death Linked to Platform